Market Closed -
Warsaw S.E.
17:03:24 28/06/2024 BST
|
5-day change
|
1st Jan Change
|
0.58
PLN
|
0.00%
|
|
0.00%
|
0.00%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
63.35
|
18.34
|
10.62
|
10.06
|
22.66
|
22.06
|
Enterprise Value (EV)
1 |
50.55
|
24.6
|
20.86
|
22.1
|
36.01
|
34.48
|
P/E ratio
|
-2.55
x
|
-0.93
x
|
-0.68
x
|
-0.63
x
|
-3.39
x
|
-5.18
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
160
x
|
21.2
x
|
18.2
x
|
52.7
x
|
52
x
|
9.85
x
|
EV / Revenue
|
127
x
|
28.4
x
|
35.8
x
|
116
x
|
82.6
x
|
15.4
x
|
EV / EBITDA
|
-2.21
x
|
-1.38
x
|
-1.74
x
|
-4
x
|
-14.7
x
|
-31.7
x
|
EV / FCF
|
-2.32
x
|
-2.17
x
|
-5.36
x
|
-27.6
x
|
-68.4
x
|
-45.2
x
|
FCF Yield
|
-43.1%
|
-46.1%
|
-18.7%
|
-3.62%
|
-1.46%
|
-2.21%
|
Price to Book
|
1.3
x
|
0.63
x
|
0.51
x
|
1.27
x
|
12.8
x
|
35.1
x
|
Nbr of stocks (in thousands)
|
9,169
|
9,169
|
19,034
|
22,258
|
25,293
|
28,393
|
Reference price
2 |
6.910
|
2.000
|
0.5580
|
0.4520
|
0.8960
|
0.7770
|
Announcement Date
|
06/04/18
|
12/04/19
|
30/06/20
|
21/07/21
|
03/05/22
|
02/05/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
0.397
|
0.866
|
0.583
|
0.191
|
0.436
|
2.24
|
EBITDA
1 |
-22.82
|
-17.79
|
-11.96
|
-5.525
|
-2.456
|
-1.086
|
EBIT
1 |
-24.01
|
-18.71
|
-13.7
|
-7.275
|
-4.267
|
-2.53
|
Operating Margin
|
-6,048.61%
|
-2,160.05%
|
-2,349.4%
|
-3,808.9%
|
-978.67%
|
-112.95%
|
Earnings before Tax (EBT)
1 |
-25.04
|
-19.84
|
-15.37
|
-15.88
|
-6.69
|
-3.872
|
Net income
1 |
-24.89
|
-19.78
|
-15.54
|
-15.99
|
-6.69
|
-3.872
|
Net margin
|
-6,270.03%
|
-2,284.3%
|
-2,665.01%
|
-8,370.68%
|
-1,534.4%
|
-172.86%
|
EPS
2 |
-2.715
|
-2.160
|
-0.8163
|
-0.7183
|
-0.2645
|
-0.1500
|
Free Cash Flow
1 |
-21.79
|
-11.35
|
-3.89
|
-0.8008
|
-0.5264
|
-0.7631
|
FCF margin
|
-5,489.64%
|
-1,310.35%
|
-667.22%
|
-419.24%
|
-120.73%
|
-34.07%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
06/04/18
|
12/04/19
|
30/06/20
|
21/07/21
|
03/05/22
|
02/05/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
6.27
|
10.2
|
12
|
13.3
|
12.4
|
Net Cash position
1 |
12.8
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-0.3523
x
|
-0.8556
x
|
-2.18
x
|
-5.435
x
|
-11.43
x
|
Free Cash Flow
1 |
-21.8
|
-11.3
|
-3.89
|
-0.8
|
-0.53
|
-0.76
|
ROE (net income / shareholders' equity)
|
-59.5%
|
-50.8%
|
-62.4%
|
-111%
|
-138%
|
-333%
|
ROA (Net income/ Total Assets)
|
-21.7%
|
-18.2%
|
-16.6%
|
-10.7%
|
-8.95%
|
-6.58%
|
Assets
1 |
114.8
|
108.4
|
93.83
|
149
|
74.77
|
58.81
|
Book Value Per Share
2 |
5.320
|
3.160
|
1.090
|
0.3600
|
0.0700
|
0.0200
|
Cash Flow per Share
2 |
2.740
|
0.5900
|
0.1200
|
0.0100
|
0
|
0
|
Capex
1 |
2
|
1.52
|
0.48
|
0.07
|
-
|
-
|
Capex / Sales
|
504.03%
|
175.64%
|
82.5%
|
35.6%
|
-
|
-
|
Announcement Date
|
06/04/18
|
12/04/19
|
30/06/20
|
21/07/21
|
03/05/22
|
02/05/23
|
|
1st Jan change
|
Capi.
|
---|
| 0.00% | 4.24M | | -42.89% | 7.8B | | +6.77% | 3.53B | | -1.35% | 2.24B | | -27.06% | 1.84B | | -21.23% | 1.66B | | +9.31% | 951M | | +29.42% | 811M | | -12.66% | 670M | | -26.12% | 533M |
Bio Diagnostics & Testing
|